Suppr超能文献

遗传性非息肉病性结直肠癌中的结直肠癌:累积终生发病率、生存率及肿瘤分布。121个已证实存在突变的家系报告。

Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations.

作者信息

Barrow E, Alduaij W, Robinson L, Shenton A, Clancy T, Lalloo F, Hill J, Evans D G

机构信息

Department of General Surgery, Manchester Royal Infirmary, Manchester, UK.

出版信息

Clin Genet. 2008 Sep;74(3):233-42. doi: 10.1111/j.1399-0004.2008.01035.x. Epub 2008 Jun 28.

Abstract

Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominant condition caused by inactivating mutations of DNA mismatch repair (MMR) genes. An accurate estimation of colorectal cancer risk for mutation carriers is essential for counselling and rationalizing screening programmes. Families were referred on the basis of clinical criteria. Tumour immunohistochemistry and microsatellite testing were performed. Appropriate patients underwent sequencing of all relevant exons of the MMR genes. Proven and obligate mutation carriers and first-degree relatives (FDRs) with an HNPCC spectrum cancer were considered mutation carriers, as were a proportion of untested, unaffected FDRs based on the proportion of unaffected relatives testing positive in each age group. The cumulative lifetime risk was calculated by Kaplan-Meier analysis. Three hundred and forty-one colorectal cancers in 839 proven, obligate, or assumed mutation carriers were analysed. The cumulative risk to age 70 years for all mutation carriers combined was 50.4% (95% CI 47.8-52.9). The cumulative risk in males was 54.3% (95% CI 50.7-57.8), which was significantly higher than in females (log rank p = 0.02) who had a risk of 46.3% (95% CI 42.8-49.9). These penetrance estimates from HNPCC families attending high-risk clinics have been corrected for ascertainment bias and are appropriate risks for those referred to a high-risk clinic. Current colonoscopic screening guidelines are appropriate.

摘要

遗传性非息肉病性结直肠癌(HNPCC)是一种常染色体显性疾病,由DNA错配修复(MMR)基因的失活突变引起。准确估计突变携带者患结直肠癌的风险对于咨询和合理制定筛查计划至关重要。根据临床标准转诊家庭。进行肿瘤免疫组织化学和微卫星检测。对合适的患者进行MMR基因所有相关外显子的测序。已证实的和必然的突变携带者以及患有HNPCC谱系癌症的一级亲属(FDR)被视为突变携带者,基于每个年龄组中未受影响亲属检测呈阳性的比例,一部分未检测、未受影响的FDR也被视为突变携带者。通过Kaplan-Meier分析计算累积终生风险。分析了839名已证实的、必然的或假定的突变携带者中的341例结直肠癌。所有突变携带者合并至70岁时的累积风险为50.4%(95%置信区间47.8 - 52.9)。男性的累积风险为54.3%(95%置信区间50.7 - 57.8),显著高于女性(对数秩检验p = 0.02),女性的风险为46.3%(95%置信区间42.8 - 49.9)。这些来自就诊于高危诊所的HNPCC家庭的外显率估计值已针对确诊偏倚进行了校正,对于转诊至高危诊所的患者而言是合适的风险。当前的结肠镜筛查指南是合适的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验